Insud Pharma
Armando Luján is an experienced engineering and project management professional with a background in architecture. Currently serving as Engineering Associate Director and previously as Engineering Manager at Insud Pharma since August 2021, Luján has a strong track record in managing large-scale pharmaceutical projects. Prior roles include Strategic Project Manager within the Pharma Unit at IDOM Consulting, where Luján oversaw significant investments in facility expansions for companies such as FAES FARMA, BAYER, and BAXTER. Earlier experience includes Lead Project Manager at AXIOM Ingeniería, where Luján directed projects for PiSA and NEOLPHARMA, and senior roles in architectural firms focused on various private and urban development projects. Luján holds a Bachelor's degree in Architecture from Universidad Politécnica de Madrid.
This person is not in the org chart
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.